drugset / Trial / NCT04106778

DMT310-003 Topical in the Treatment of Acne Vulgaris

NCT04106778

Phase 2 Completed 181 enrolled Dermata Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.

Timeline

Start
2019-10-10
Primary completion
2020-05-04
Completion
2020-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject DMT310 Unknown Topical

Indications